Politico looks at the warning signs around Health Secretary Kennedy's move to let six peptides that lack FDA approval reach the US market.
Recap by typeshit. Full story at Politico.
The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
Maria David Patten alleges Novo hid NAION risks; her case joins the federal MDL before Judge Karen Marston in Pennsylvania, where bellwether trials are expected.
HHS now lets pharmacies compound BPC-157, TB-500 and four others, but BoxingInsider notes all six remain on WADA's banned list for licensed boxers.
Per @pamelajeannoble, the letter flags contamination risks, manufacturing conditions and compounded copies resembling approved drugs.
The Houston compounding firm is pulling its tirzepatide and niacinamide injection because sterility couldn't be assured, and the vials had shipped nationwide.
UBS says volumes grew about 55% while net prices fell roughly 14%, and points to about 500,000 people joining Lilly's Medicare bridge program in a few months.
Loading…